Stock comparison
Haemonetics
West Pharmaceutical Services
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
WST
West Pharmaceutical Services
Market cap
$22.35B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | WST | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 58C | HAE |
| Benjamin Graham | 85A | 88A | WST |
| Philip Fisher | 60C | 47D | HAE |
| Peter Lynch | 54C | 24F | HAE |
| Joel Greenblatt | 31F | 60C | WST |
| Charlie Munger | 54D | 60C | WST |
| Terry Smith | 55D | 54C | HAE |
Side-by-side metrics
| Metric | HAE | WST |
|---|---|---|
| Market cap | $2.98B | $22.35B |
| P/E (TTM) | 24.8x | 39.8x |
| EV/EBIT | 14.1x | 34.0x |
| ROIC (TTM) | 8.37% | 15.24% |
| Gross margin | 55.74% | 36.24% |
| Net margin | 7.29% | 16.85% |
| Revenue CAGR 5y | 7.65% | 2.08% |
| EPS CAGR 5y | 24.62% | -6.4% |
| Debt / Equity | 1.5x | 0.1x |
| Dividend yield | 0.0% | 0.29% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -6.4%+126%
- Revenue CAGR 5y7.65%vs 2.08%+73%
- EV/EBIT14.1xvs 34.0x+59%
- P/E (TTM)24.8xvs 39.8x+38%
WST leads on
- Dividend yield0.29%vs 0.0%+100%
- Debt / Equity0.1xvs 1.5x+93%
- Market cap$22.35Bvs $2.98B+87%
- Net margin16.85%vs 7.29%+57%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.